'On consolidated basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Dr Reddys Laboratories has increased 15.81% to Rs 8381.2 crore. Sales of Pharmaceutical Services segment has gone down 1.82% to Rs 1,038.70 crore (accounting for 12.10% of total sales). Sales of Global Generics segment has gone up 16.93% to Rs 7,381.30 crore (accounting for 86.02% of total sales). Sales of Others segment has gone up 32.84% to Rs 161.40 crore (accounting for 1.88% of total sales). Inter-segment sales came down from Rs 255.10 crore to Rs 200.20 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 16.23% to Rs 4,905.60 crore. PBIT of Pharmaceutical Services segment rose 2.25% to Rs 235.90 crore (accounting for 4.81% of total PBIT). PBIT of Global Generics segment rose 15.72% to Rs 4,521.90 crore ...
Pleaselogin & subscribe to view the full report.
More Reports
|
|